MS4A1 and neoplasm: We revealed that MYC can blunt the efficacy of immunotherapeutic approaches via target antigen downregulation in the case of CD20, but also via induction of tumor intrinsic resistance towards NK cell- and T cell-mediated cytotoxicity by upregulating anti-apoptotic pathways and suppressing T-cell activation.